SERICIN AS A CHOLINERGIC MODULATOR IN ALZEIMER'S DISEASE INDUCED RAT
Keywords:
Silk protein, Sericin, Nil, Morphometric aspects, Cognitive aspects, Cholinergic systemAbstract
Objective: Alzheimer's disease (AD), characterized by formation of Amyloid plaques, neurofibrillary tangles and loss of neurons in the cerebral cortex and certain sub-cortical regions eventually results in gross atrophy of the affected regions, including degeneration in cholinergic regions. According to Cholinergic hypothesis, AD is caused by reduced synthesis of the neurotransmitter ACh, wherein the AChE levels were increased which causes damage to the cholinergic neurons finally leading to cognitive impairments. Today most of the drugs available in the market are Cholinesterase inhibitors to treat AD, these drugs temporarily de accelerate the progressive cognitive decline in some AD cases but not all other forms of dementia. Research on Alzheimer's proven the importance of the Antioxidants and AChEI to treat AD. To cure AD effectively it is necessary to identify a natural product with Antioxidant and AChEI activity. The Silk Protein, Sericin a natural protein has wide applications in the Pharma industry.
Methods: The present study was aimed to evaluate potential AChE inhibitor†activity of Sericin in AD-induced rat model by conducting experiments mainly on the Cholinergic system and also on the Morphometric and Cognitive aspects in control and experimental rats.\
Results: The results of the present study demonstrated that Sericin could effectively counteract the AChE activity in AD-induced rat and retains the ACh levels in the brain cholinergic regions. In the end of the experiment AD-induced rat showed recovery tendency in Morphometric and Cognitive aspects are the passive evidence for decline AD-induced AChE levels.
Conclusion: From this study, it may suggest that Sericin act as a potential Cholinesterase inhibitor in AD.
Â
Â
Downloads
References
Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960’s. Neurobiol Aging. 1998;19(3):173-89.
Shen ZX. Brain cholinesterases: II. The molecular and cellular basis of Alzheimer’s disease. Med Hypotheses 2004;63(2):308–21.
Wenk GL. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 2003;64(9):7–10.
Akhondzadeh S, Noroozian M. Alzheimer’s disease: Pathophysiology and pharmacotherapy. I Drugs 2002;4:1167-72.
Bullock R. New drugs for Alzheimer’s disease and other dementias. Br J Psychiatry 2002;180:135-9.
Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003;306:821–7.
Musial A, Bajda M, Malawska B. Recent developments in cholinesterases inhibitors for Alzheimer′s disease treatment. Curr Med Chem 2007;14:2654–79.
Phillipson JD. Phytochemistry and medicinal plants. Phytochem 2001;56(3):237–43.
Rates SMK. Plants as source of drugs. Toxicon 2001;39(5):603–13.
Gulrajani ML. Sericin: A bio-molecule of value, Souveni 20th Congress of the international sericultural commission. Bangalore, India; 2005. p. 21-9.
Yao WH, Chen JC, Hu MS, Teng MY, Huang PH, Lin JM, Chen CC. Crosslinking of cotton cellulose in the presence of serine and glycine–Physical properties and reaction kinetics. J App Polym Sci 2005;97:595-603.
Behringer MP. Laboratory care of vertebrates. In: Techniques and materials in biology, Mc Graw Hill. Inc, New York; 1973. p. 171-4.
Wei H, Li L, Song Q, Ai H, Chu J, Li W. Behavioural study of the D-Galactose induced mouse aging model in C57BL/6J mice. Behave Brain Res 2005;157:245-51.
Hua Xiangdong, Ming Lei, Jiong Ding, Qunying Han, Gang Hu, Ming Xiao. Pathological and biochemical alterations of astrocytes in ovariectomized rats injected with D-Galactose: A potential contribution to Alzheimer’s disease Processes. Exp Neurol 2008;210:709-18.
Banks WA, Nichoff ML, Drago D. Aluminium complexing enhances amyloid beta protein penetration of blood brain barrier. Brain Res 2006;1116(1):215-21.
Selkoe DJ. Alzheimer’s disease: Genes, proteins and therapy. Physiol Rev 2001;81(2):741-66.
Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature 2004;430(7000):631-9.
Goedert M, Spillantini MG. A century of Alzheimer’s disease. Sci 2006;314(5800):777-81.
Cui X, Zuo P, Zhang Q, Li X, Hu Y, Long J, et al. Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid. J Neurosci Res 2006;83(8):1584–90.
Lei M, Hua X, Xiao M, Ding J, Han Q, Hu G. Impairments of astrocytes are involved in the D-galactose-induced brain aging. Biochem Biophys Res Commun 2008;369:1082-7.
Baynes JW. The role of AGEs in aging: causation or correlation. Exp Gerontol 2001;36:1527-37.
Zhang D, Liu GT, Shi JG, Zhang JJ. Coeloglossum viride var bracteatum extract attenuates D-Galactose and NaNO2 induced memory impairment in mice. J Ethnopharmacol 2006;104:250-6.
Fang F, Liu G. A novel cyclic squamosamide analogue compound FLZ improves memory improvement in artificial senescence mice induced by chronic injection of D-Gal and NaNO2. Basic Clin Pharmacol Toxicol 2007;101:447-54.
Ho SC, Lu JH, Wu Ry. Establishment of the mimetic aging effect in mice acused by D-galactose. Biogerontol 2003;4(1):15-8.
Cui X, Zuo P, Zhang Q, Li X, Hu Y, Long J, et al. Chronic systemic D-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid. J Neurosci Res 2006;83(8):1584–90.
Joung-Ho Moon, Kyoung-Ho Pyo, Bong-Kwang Jung, Hyang Sook Chun, Jong-Yil Chai, Eun-Hee Shin. Resistance to toxoplasma gondii infection in mice treated with silk protein by enhanced immune responses. Korean J Parasitoal 2011;49(3):303-8.
Zhang ZX, Zahner GE, Roman GC. Socio-demographic variation of dementia subtypes in China: Methodology and results of a prevalence study in Beijing, Chengdu, Shanghai and Xian. Neuroepidemiol 2006;27:177-87.
Hua XD, Lei M, Zhang YJ, Ding J, Han QY, Hu G. Long-term D-Galactose injection combines with ovirectomy serves as a new rodent model for Alzheimer’s disease. Life Sci 2007;80:1897-905.
Morris R. Developments of a water maze procedure for studying spatial learning in the rat. Neurosci Methods 1984;11:47-64.
Glowinski J, Iversen LL JA. Storage and synthesis of norepinephrine in the reserpine-treated rat brain. J Pharmacol Exp Ther 1966;151(3):385-99.
Metcalf RL. In: Methods of biochemical analysis. Vol: 5th Edition. Click Interscience publishers Inc. New York; 1957.
Augustinsson KB. In: Methods of Biochemical Analysis (ed. D. Click). Inter Science Publishers. New York; 1957;5:1.
Ellman GL, Courtney KD, Featherstone RM. A new and rapid calorimetric determination of acetylcholinesterase activity. J Biochem Pharmacol 1961;7:88-95.
Moser E, Moser MB, Andersen P. Spatial; earning impairment parallels the magnitude of dorsal hippocampal lesions, but is hardly present following ventral lesions. J Neurosci 1993;13:3916-25.
Bartus RT. On neurodegenerative diseases models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000;163:495-529.
Colom LV. Septal networks: Relevance to theta rhythm, epilepsy and Alzheimer’s disease. J Neurochem 2006;96:609-23.
Muir JL. Acetylcholine, aging and Alzheimer’s disease. Pharmacol Biochem Behav 1997;56(4):687-96.
Dongsun Park, Sun Hee Lee, Young Jin Choi, Dae Kwon Bae, Yun Hui Yang, Goeun Yang, et al. Improving effect of silk peptides on the cognitive function of rats with aging brain facilitated by D-Galactose. Biomol Ther 2011;19(2):224-30.
Shin S, Yeon S, Park D, Oh J, Kang H, Kim S, et al. Silk amino acids improve physical stamina and male reproductive function of mice. Biol Pharm Bull 2009b; 33:273-8.
Shin S, Park D, Yeon S, Jeon JH, Kim TK, Joo SS, et al. Stamina-enhancing effects of silk amino acid preparations in mice. Lab Anim Res 2009a; 25:127-34.
Park Dongsun, Sun Hee Lee, Young Jin Choi, Dae Kwon Bae, Yun Hui Yang, Goeun Yang, et al. Improving effect of silk peptides on the cognitive function of rats with aging brain facilitated by D-Galactose. Biomol Ther 2011;19(2):224-30.
Milatovic D, WD Dettbarn. Modification of acetylcholinesterase during adaptation to chronic, subacute paraoxon application in rat. Toxicol Appl Pharmacol 1996;136:20-8.
Francis R, McGrath G, Zhang J, Ruddy DA, Sym M, Apfeld J, et al. aph-1 and pen-2 are required for Notch pathwaysignaling, gamma-secretase cleavage of beta-APP, and presenilin protein accumulation. Dev Cell 2002;3:85-97.
Perry G, Kawai M, Tabaton M, Onorato M, Mulvihill P, Richey P, et al. Neuropil threads of Alzheimer’s disease show a marked alteration of the normal cytoskeleton. J Neurosci 1991;11:1748–55.
Dongsun Park, Sun Hee Lee, Young Jin Choi, Dae Kwon Bae, Yun Hui Yang, Goeun Yang, et al. Improving effect of silk peptides on the cognitive function of rats with aging brain facilitated by D-Galactose. Biomol Ther 2011;19(2):224-30.
Park D, Kim TK, Yeon S, Lee SH, Choi YJ, Bae DK, et al. Tyrosine-fortiï¬ ed silk amino acids improve physical function of Parkinson’s disease rats. Food Sci Biotechnol 2010;20:79-84.
Greig N, Utsuki T, Ingram D, Wang Y, Pepeu G, Scali C. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci India Sect. 2005;102:17213-8.
Niewiadomska G, Baksalerska-Pazera M, Riedal G. The septo hippocampal system, learning and recovery of function. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:791-805.
Bacciottini L, Passani M, Mannaioni P, Blandina P. Interactions between histaminergic and Behavioural. Brain Res 2001;124:183-94.